In the early afternoon on Friday, November 2, AcelRx's (NASDAQ: ACRX) shares were halted by NASDAQ pending news from the company. Around an hour later, ACRX released a press release announcing that the company's lead drug candidate Dsuvia had been approved by the FDA for the treatment of acute pain in medically supervised settings. ACRX plans to hold a conference call at 8:30AM on Monday, November 5, to discuss the approval of Dsuvia and the company's third quarter financial results (which the company disclosed in a second press release on Friday). After opening